Financial Performance - The company's operating revenue for Q3 2024 was ¥2,269,451,419.21, a decrease of 55.59% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥278,982,753.43, with a year-to-date net profit of -¥818,989,156.63[2]. - Basic and diluted earnings per share for Q3 2024 were both -¥0.32, with year-to-date figures at -¥0.94[3]. - The company reported a significant reduction in operating revenue due to decreased scale in the feed and food sectors and a reduction in live pig output[5]. - The company's revenue for the same period was CNY 6,925.14 million, representing a year-on-year decline of 54.37%[9]. - The net profit attributable to shareholders was a loss of CNY 818.99 million during the reporting period[9]. - The decline in revenue was primarily due to reduced sales in the feed, food, and raw material trading segments, as well as a decrease in pig output[9]. - Total operating revenue for the first three quarters of 2024 was CNY 6,925,141,428.12, a decrease from CNY 15,176,655,806.29 in the same period of 2023, representing a decline of approximately 54.4%[17]. - The company reported a net loss of CNY 919,619,480.22 for the first three quarters of 2024, compared to a net loss of CNY 1,545,981,548.03 in the same period of 2023[17]. - The total comprehensive loss for the current period is -953,439,434.69 RMB, compared to -1,533,950,904.61 RMB in the previous period, indicating a reduction of about 37.7%[18]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥11,812,989,678.24, down 13.30% from the end of the previous year[3]. - As of September 30, 2024, the company's current assets totaled CNY 2,288.03 million, down from CNY 2,789.12 million at the end of 2023[12]. - The total assets of the company as of the end of the reporting period were CNY 11,812,989,678.24, down from CNY 13,625,213,490.65 in the previous year[15]. - Total liabilities decreased to CNY 13,262,759,395.29 from CNY 14,128,429,997.37, showing a decline of about 6.1%[15]. - The company’s equity attributable to shareholders was reported at CNY -1,819,124,196.35, compared to CNY -962,969,028.19 in the previous year, indicating a worsening financial position[15]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥155,362,935.60, reflecting a decrease of 76.51% compared to the previous year[2]. - Cash flow from operating activities for the first three quarters of 2024 is 155,362,935.60 RMB, down from 661,293,989.95 RMB in the same period of 2023, reflecting a decline of approximately 76.6%[20]. - Cash inflow from operating activities totaled 7,334,289,947.79 RMB, while cash outflow was 7,178,927,012.19 RMB, resulting in a net cash flow of 155,362,935.60 RMB[20]. - The net cash flow from financing activities is 50,378,894.08 RMB, a significant recovery from -698,451,865.36 RMB in the previous period[21]. - The total cash and cash equivalents at the end of the period is 335,867,519.81 RMB, up from 197,084,967.25 RMB at the end of the previous period, indicating an increase of approximately 70.5%[21]. Operational Changes and Challenges - The company is currently in a pre-restructuring bankruptcy phase, which has significantly impacted its business scale and financial performance[5]. - The company has actively shut down and transferred non-core development areas and low-efficiency pig farms to optimize production capacity[5]. - The company has a large amount of idle assets, leading to heavy depreciation and amortization burdens, alongside normal interest accruals on bank financing[5]. - The company is undergoing a pre-restructuring process initiated in February 2024 due to liquidity issues and debt risks[10]. - The company aims to improve operational performance and resolve debt issues through restructuring efforts[11]. - The company has faced significant losses over the past three years, prompting a focus on core business areas and operational stability[10]. - The company has not yet received court approval for its restructuring process, leaving its future uncertain[11]. Research and Development - Research and development expenses decreased to CNY 40,505,601.02 in 2024 from CNY 113,451,727.49 in 2023, reflecting a reduction of approximately 64.3%[17]. Future Outlook - The company has not provided specific guidance for future performance or new product developments in the current report[16]. - The company has implemented new accounting standards starting in 2024, which may affect future financial reporting[22].
傲农生物(603363) - 2024 Q3 - 季度财报